Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Abstract Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, randomized, placebo-controlled DISCOVER-2 study enrolled...

Full description

Bibliographic Details
Main Authors: Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Rheumatology
Subjects:
Psoriatic arthritis
Biologics
Guselkumab
Minimal disease activity
Online Access:https://doi.org/10.1186/s41927-024-00375-w

Internet

https://doi.org/10.1186/s41927-024-00375-w

Similar Items